Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model

Thrombosis and Haemostasis

Volumn 96, Issue 3, 2006, Pages 371-377

  Sorg, Heiko ^a   Hoffmann, Johannes N ^b   Menger, Michael D ^c   Lindenblatt, Nicole ^a   Goehring, Peter ^b   Vollmar, Brigitte ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Ear model; Hairless mouse; Intravital fluorescence microscopy; Light dye injury; Occlusion rate

Indexed keywords

ANTITHROMBIN III CONCENTRATE; HEPARIN; HIRUDIN; LEPIRUDIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERIOLE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLUORESCENCE MICROSCOPY; IN VIVO STUDY; MALE; MICROANGIOPATHY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THROMBOGENESIS; THROMBOSIS; VENULE;

ANIMALS; ANTITHROMBINS; DISEASE MODELS, ANIMAL; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HOMOZYGOTE; KINETICS; MALE; MICE; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; THROMBOSIS; TREATMENT OUTCOME;

EID: 33748602905     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-02-0118     Document Type: Article

References (42)

1. Wenzel RP. Treating sepsis. N Engl J Med 2002; 347: 966-7.
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-S116.
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
4. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28: S9-S11.
5. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
6. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004; 36: 41-9.
7. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost 2004; 91: 213-24.
8. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004; 30: 1032-40.
9. Fourrier F, Jourdain M, Tournois A, et al. Coagulation inhibitor substitution during sepsis. Intensive Care Med 1995; 21: S264-S268.
10. Mackman N. Regulation of tissue factor gene expression in human monocytic and endothelial cells. Haemostasis 1996; 26: 17-9.
11. Roemisch J, Gray E, Hoffmann IN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-70.
12. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
13. Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Tbromb Haemost 1984; 51: 232-5.
14. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Haemost 1998; 24: 61-9.
15. Emerson TE Jr, Fournel MA, Leach WJ, et al. Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. Circ Shock 1987; 21: 1-13.
16. Hoffmann JN, Vollmar B, Inthorn D, et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279: C98-C1O7.
17. Iba T, Kidokoro A, Fukunaga M, et al. Antithrombin modulates the leukocyte-endothelial cell interaction in the staphylococcal enterotoxin B-challenged mouse. J Trauma 2003; 55: 546-50.
18. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombiri III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
19. Uchiba M, Okajima K, Murakami K, et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: L921-930.
20. Hoffmann JN, Vollmar B, Romisch J, et al. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30: 218-25.
21. Hoffmann JN, Vollmar B, Laschke MW, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-52.
22. Warren BL, Eid A, Singer P, et al. and the KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-78.
23. Dellinger RP, Carlet JM, Masur H, et al. and the Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-73.
24. Roesken F, Ruecker M, Vollmar B, et al. A new model for quantitative in vivo microscopic analysis of thrombus formation and vascular recanalisation: The ear of the hairless (hr/hr) mouse. Thromb Haemost 1997; 78: 1408-14.
25. Fiebig E, Ley K, Arfors KE. Rapid leukocyte accumulation by "spontaneous" rolling and adhesion in the exteriorized rabbit mesentery. Int J Microcirc Clin Exp 1991; 10: 127-44.
26. Valenzeno DR Photomodification of biological membranes with emphasis on singlet oxygen mechanisms. Photochem Photobiol 1987; 46: 147-60.
27. Osterlund M, Owenius R, Carlsson K, et al. Probing inhibitor-induced conformational changes along the interface between tissue factor and factor VIIa. Biochemistry 2001; 40: 9324-8.
28. Engelmann B, Luther T, Mueller I. Intravascular tissuefactor pathway- a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8.
29. Inamo J, Belougne E, Doutremepuich C. Importance of photo activation of rose bengal for platelet activation in experimental models of photochemically induced thrombosis. Thromb, Res 1996; 83: 229-35.
30. Roesken F, Vollmar B, Ruecker M, et al. In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recarialization. J Vasc Surg 1998; 28: 498-505.
31. Vargas Hein O, von Heymann C, Lipps M, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 2001; 27: 673-9.
32. Broeders MA, Tangelder GJ, Slaaf DW, et al. Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules. Arterioscler Thromb Vasc Biol 2001; 21: 163-9.
33. Harada N, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/ reperftision-induced liver injury in ratsby activation of cyclooxygenase-1. Thromb, Haemost 2004; 92: 550-8.
34. Nowak G, Bucha E, Goock T, et al. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-15.
35. Estes JW Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204-20.
36. Knot EA, de Jong E, ten Cate JW, et al. Antithrombin III: biodistribution, in healthy volunteers. Thromb, Haemost 1987; 58: 1008-11.
37. Lu W, Mant T, Levy JH, et al. Pharmacokinetics of recombirtant tratisgenic antithrombin in volunteers. Anesth Analg 2000; 90: 531-4.
38. Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 1998; 9 Suppl 2: S25-37.
39. Isobe H, Okajima K, Uchiba M, et al. Antithrombin prevents endotoxin-induced bypotension by inhibiting the induction of nitric oxide synthase in rats. Blood 2002; 99: 1638-45.
40. Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/ reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-36.
41. Hoffmann JN, Vollmar B, Inthorn D, et al. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure. Shock 2000; 5: 528-34.
42. Hoffmann JN, Wiedermann CJ, Juers M, et al. and the KyberSept investigators. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95: 850-6.